Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

10.53USD
2:05pm EDT
Change (% chg)

$-0.29 (-2.68%)
Prev Close
$10.82
Open
$10.72
Day's High
$10.72
Day's Low
$10.50
Volume
3,552
Avg. Vol
13,181
52-wk High
$11.34
52-wk Low
$5.70

Latest Key Developments (Source: Significant Developments)

Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​
Tuesday, 5 Sep 2017 06:00am EDT 

Sept 5 (Reuters) - Oramed Pharmaceuticals Inc :‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation​.‍At meeting, FDA gave guidance that regulatory pathway for submission of ORMD-0801, would be a biologics license application​.In addition, FDA confirmed company's ability to use insulin from different suppliers like HTBT in phase 3 study.  Full Article

Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons
Friday, 21 Jul 2017 06:32am EDT 

July 21 (Reuters) - Oramed Pharmaceuticals Inc ::Oramed Pharmaceuticals Inc - on July 18, yifat zommer, cfo of co resigned from her positions with co per personal reasons, effective August 1, 2017.Oramed Pharmaceuticals Inc says on July 19, appointed hilla eisenberg to serve as CFO, treasurer and secretary, effective August 1, 2017 .Oramed Pharmaceuticals Inc - prior to her appointment, eisenberg served as company's finance manager from March 2016 until July 2017.  Full Article

Oramed announces end-of-phase 2 meeting with FDA to initiate phase 3 program
Tuesday, 11 Jul 2017 08:50am EDT 

July 11 (Reuters) - Oramed Pharmaceuticals Inc ::Oramed announces end-of-phase 2 meeting with FDA to initiate phase 3 program.Oramed Pharmaceuticals-‍phase IIB trial met primary & secondary endpoints by indicating a statistically significant lowering of glucose relative to placebo​.Oramed - ‍FDA agreed to schedule an end-of-phase II meeting with co for phase IIB trial of oral insulin capsule ORMD-0801 in treatment of type 2 diabetes​.Oramed Pharmaceuticals Inc says end-of-phase II meeting is expected to take place on August 31, 2017.Oramed Pharmaceuticals-FDA agreed to schedule end-of-phase II meeting with co for completed phase IIB trial of ORMD-0801 in treatment of type 2 diabetes​.  Full Article

Oramed announces dual-listing on Tel Aviv stock exchange
Wednesday, 5 Jul 2017 08:50am EDT 

July 5 (Reuters) - Oramed Pharmaceuticals Inc :Oramed announces dual-listing on Tel Aviv stock exchange.Oramed Pharmaceuticals Inc - ‍Based on current market capitalization of company, it is expected that Oramed will be included in TA SME-60 index​.Oramed Pharmaceuticals Inc - Oramed common stock will continue to be listed and traded on Nasdaq capital markets.  Full Article

Oramed receives Israel regulatory approval
Tuesday, 2 May 2017 08:45am EDT 

May 2 (Reuters) - Oramed Pharmaceuticals Inc : :Oramed receives Israel regulatory approval to conduct human study for new oral leptin capsule.Oramed Pharmaceuticals-Israel's ministry of health approved Oramed's commencement of proof of concept single dose study for its oral leptin drug candidate.  Full Article

Oramed Pharmaceuticals Inc files for mixed shelf of up to $100 mln
Wednesday, 11 Jan 2017 05:34pm EST 

Oramed Pharmaceuticals Inc :Oramed pharmaceuticals inc - files for a mixed shelf of up to $100 million - sec filing.  Full Article

Oramed Pharmaceuticals unit enters into service agreement with XERTECS GmbH
Thursday, 16 Jun 2016 11:57am EDT 

Oramed Pharmaceuticals Inc : On June 13, 2016, Oramed Ltd entered into a service agreement with XERTECS GmbH .As consideration for XERTECS services, subsidiary will pay XERTECS a total amount of up to EUR 2.36 million.  Full Article

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* ‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation​